Francesco Rodeghiero

Summary

Affiliation: San Bortolo Hospital
Country: Italy

Publications

  1. ncbi request reprint Treatment of von Willebrand disease
    Francesco Rodeghiero
    Department of Hematology and Hemophilia and Thrombosis Center, San Bortolo Hospital, Vicenza, Italy
    Semin Hematol 42:29-35. 2005
  2. ncbi request reprint Effect of DCEP mobilizing regimen in in vivo purging of PBSC harvests in multiple myeloma
    Elisabetta Novella
    Leuk Lymphoma 45:1497-9. 2004
  3. ncbi request reprint The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study
    F Rodeghiero
    Hematology Department, S Bortolo Hospital, Vicenza, Italy
    J Thromb Haemost 3:2619-26. 2005
  4. ncbi request reprint Chronic immune thrombocytopenic purpura. New agents
    F Rodeghiero
    Department of Cell Therapy and Hematology, San Bortolo Hospital, Via Rodolfi 37, I 36100 Vicenza, Italy
    Hamostaseologie 29:76-9. 2009
  5. ncbi request reprint ITP and international guidelines: What do we know, what do we need?
    Francesco Rodeghiero
    San Bortolo Hospital, Department of Cell Therapy and Hematology, 36100 Vicenza, Italy Electronic address
    Presse Med 43:e61-7. 2014
  6. doi request reprint Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group
    Francesco Rodeghiero
    Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy
    Blood 121:2596-606. 2013
  7. doi request reprint Von Willebrand disease: pathogenesis and management
    Francesco Rodeghiero
    Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy
    Thromb Res 131:S47-50. 2013
  8. ncbi request reprint Short- and long-term risks of splenectomy for benign haematological disorders: should we revisit the indications?
    Francesco Rodeghiero
    Department of Cell Therapy and Haematology, San Bortolo Hospital, Vicenza, Italy
    Br J Haematol 158:16-29. 2012
  9. ncbi request reprint Ifosfamide in hematological malignancies of adults
    F Rodeghiero
    Department of Hematology, San Bortolo Hospital, Vicenza, Italy
    Oncology 65:85-93. 2003
  10. doi request reprint Management of menorrhagia in women with inherited bleeding disorders: general principles and use of desmopressin
    F Rodeghiero
    Department of Cellular Therapy and Hematology, Thrombosis and Hemostasis Center, San Bortolo Hospital, Vicenza, Italy
    Haemophilia 14:21-30. 2008

Detail Information

Publications112 found, 100 shown here

  1. ncbi request reprint Treatment of von Willebrand disease
    Francesco Rodeghiero
    Department of Hematology and Hemophilia and Thrombosis Center, San Bortolo Hospital, Vicenza, Italy
    Semin Hematol 42:29-35. 2005
    ....
  2. ncbi request reprint Effect of DCEP mobilizing regimen in in vivo purging of PBSC harvests in multiple myeloma
    Elisabetta Novella
    Leuk Lymphoma 45:1497-9. 2004
  3. ncbi request reprint The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study
    F Rodeghiero
    Hematology Department, S Bortolo Hospital, Vicenza, Italy
    J Thromb Haemost 3:2619-26. 2005
    ..The aim of this study was the validation of the criteria defining a significant mucocutaneous-bleeding history in type 1 von Willebrand disease (VWD)...
  4. ncbi request reprint Chronic immune thrombocytopenic purpura. New agents
    F Rodeghiero
    Department of Cell Therapy and Hematology, San Bortolo Hospital, Via Rodolfi 37, I 36100 Vicenza, Italy
    Hamostaseologie 29:76-9. 2009
    ..It seems however that a new paradigm in the treatment of ITP has been established where the focus is not on reducing platelet consumption but on increasing platelet production...
  5. ncbi request reprint ITP and international guidelines: What do we know, what do we need?
    Francesco Rodeghiero
    San Bortolo Hospital, Department of Cell Therapy and Hematology, 36100 Vicenza, Italy Electronic address
    Presse Med 43:e61-7. 2014
    ..The ultimate lesson of the insufficient evidence and disagreement among experts is that management of ITP should be tailored to the individual patients. ..
  6. doi request reprint Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group
    Francesco Rodeghiero
    Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy
    Blood 121:2596-606. 2013
    ..The SMOG system provides a consistent description of the bleeding phenotype in ITP, and the IWG unanimously supports its adoption and validation in future clinical studies...
  7. doi request reprint Von Willebrand disease: pathogenesis and management
    Francesco Rodeghiero
    Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy
    Thromb Res 131:S47-50. 2013
    ..Special consideration should be deserved to the treatment of menorrhagia and parturition...
  8. ncbi request reprint Short- and long-term risks of splenectomy for benign haematological disorders: should we revisit the indications?
    Francesco Rodeghiero
    Department of Cell Therapy and Haematology, San Bortolo Hospital, Vicenza, Italy
    Br J Haematol 158:16-29. 2012
    ..However, a splenectomy-sparing approach is also emerging for ITP, and recent guidelines recommend that this procedure is deferred until ≥ 12 months from ITP diagnosis, to allow sufficient time for possible remission...
  9. ncbi request reprint Ifosfamide in hematological malignancies of adults
    F Rodeghiero
    Department of Hematology, San Bortolo Hospital, Vicenza, Italy
    Oncology 65:85-93. 2003
    ..Ifosfamide-based regimens are also being evaluated in the treatment of newly diagnosed patients in sequential, response-based protocols, using many non-cross-resistant drugs...
  10. doi request reprint Management of menorrhagia in women with inherited bleeding disorders: general principles and use of desmopressin
    F Rodeghiero
    Department of Cellular Therapy and Hematology, Thrombosis and Hemostasis Center, San Bortolo Hospital, Vicenza, Italy
    Haemophilia 14:21-30. 2008
    ....
  11. ncbi request reprint Relevance of quantitative assessment of bleeding in haemorrhagic disorders
    F Rodeghiero
    Department of Cell Therapy and Hematology, Hemophilia and Thrombosis Center, San Bortolo Hospital, Vicenza, Italy
    Haemophilia 14:68-75. 2008
    ..Finally, Dr James will review the development of quantitative analysis in children, a particularly important and difficult application, but one that needs to be tackled urgently...
  12. ncbi request reprint Laboratory issues in bleeding disorders
    F Rodeghiero
    Department of Cell Therapy and Hematology, Hemophilia and Thrombosis Center, San Bortolo Hospital, Vicenza, Italy
    Haemophilia 14:93-103. 2008
    ..The most needed areas concern VWD and platelet function disorders, which suffer from inadequate diagnostic standardization, hampering widespread diagnostic capability in both Western and non-Western countries...
  13. doi request reprint Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
    Francesco Rodeghiero
    Department of Hematology, San Bortolo Hospital, Vicenza, Italy
    Blood 113:2386-93. 2009
    ....
  14. ncbi request reprint How to estimate bleeding risk in mild bleeding disorders
    F Rodeghiero
    Department of Hematology and Hemophilia and Thrombosis Center, San Bortolo Hospital, Vicenza, Italy
    J Thromb Haemost 5:157-66. 2007
    ..Innovative approaches, combining into a single probability phenotypic and genetic data, could possibly estimate better the bleeding risk in specific disorders...
  15. ncbi request reprint von Willebrand disease: still an intriguing disorder in the era of molecular medicine
    F Rodeghiero
    Department of Hematology, Hemophilia and Thrombosis Center, San Bortolo Hospital, Vicenza, Italy
    Haemophilia 8:292-300. 2002
    ....
  16. ncbi request reprint Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD)
    A Tosetto
    San Bortolo Hospital, Vicenza, Italy
    J Thromb Haemost 5:715-21. 2007
    ..However, quantitative analysis of the importance of VWF antigen (VWF:Ag) and ristocetin cofactor activity (VWF:RCo) levels in the diagnosis is lacking...
  17. doi request reprint How I treat von Willebrand disease
    Francesco Rodeghiero
    Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy
    Blood 114:1158-65. 2009
    ..On the basis of these results and through a series of illustrative examples, the clinician will be able to select the best approach for the optimal management of VWD, according to the patient's characteristics and clinical circumstances...
  18. ncbi request reprint Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria
    Alessandra Carobbio
    Hematology Department, Ospedali Riuniti di Bergamo, Largo Barozzi 1, Bergamo, Italy
    Blood 116:1051-5. 2010
    ..The actuarial probability of thrombosis was significantly influenced by leukocytosis (P = .017) and not by platelet count, indicating that platelet number does not seem of prime relevance in the definition of ELN response...
  19. ncbi request reprint A study on mutual interaction between cytokine induced killer cells and umbilical cord-derived mesenchymal cells: Implication for their in-vivo use
    Katia Chieregato
    Advanced Cellular Therapy Laboratory, Department of Cellular Therapy and Hematology, San Bortolo Hospital, Via Rodolfi 37, 36100 Vicenza, Italy
    Blood Cells Mol Dis 49:159-65. 2012
    ..In the light of our observations, when CIK and UC-MSC will be used in clinical trials, timing and sequencing of their infusion should be considered...
  20. doi request reprint The impact of bleeding history, von Willebrand factor and PFA-100(®) on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM-1VWD
    Giancarlo Castaman
    Department of Haematology, San Bortolo Hospital, Vicenza, Italy
    Br J Haematol 151:245-51. 2010
    ....
  21. doi request reprint B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities
    Erika Falisi
    Department of Hematology and Cell Therapy, S Bortolo Hospital, Vicenza, Italy
    Hematol Oncol 32:22-30. 2014
    ..Together with the extremely high frequency of stereotyped BCRs and RS transformation, these abnormalities appear to cluster in these CLL patients with additional chromosome 12, suggesting a connection with the prognosis of the disease...
  22. ncbi request reprint Production of human platelet lysate by use of ultrasound for ex vivo expansion of human bone marrow-derived mesenchymal stromal cells
    Martina Bernardi
    Advanced Cellular Therapy Laboratory, Department of Cellular Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy
    Cytotherapy 15:920-9. 2013
    ..The process is time-consuming and not well standardized. A new method for obtaining PL that is based on the use of ultrasound is proposed...
  23. doi request reprint Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation
    Carlo Visco
    Department of Hematology, San Bortolo Hospital, Via Rodolfi 37, 36100 Vicenza, Italy
    J Clin Oncol 31:1442-9. 2013
    ..In this phase II study, we combined cytarabine with R and B (R-BAC) in patients with MCL age ≥ 65 years who were previously untreated or relapsed or refractory (R/R) after one prior immunochemotherapy treatment...
  24. doi request reprint The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines
    Carlo Visco
    Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy
    Blood Cells Mol Dis 48:68-75. 2012
    ..The strong synergistic effect of bendamustine and cytarabine on MCL cells provides a rationale for developing schedules combining these agents in the treatment of MCL...
  25. ncbi request reprint Prolonged overall survival with second on-demand autologous transplant in multiple myeloma
    Francesca Elice
    Department of Hematology, San Bortolo Hospital, Vicenza, Italy
    Am J Hematol 81:426-31. 2006
    ..9% after the first ASCT but no deaths occurred after the second. Our experience suggests that elective up-front single ASCT followed by second ASCT after relapse or progression is a safe and effective global strategy to treat MM patients...
  26. doi request reprint Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines
    Silvia Castegnaro
    Department of Cellular Therapies and Hematology, San Bortolo Hospital, Vicenza, Italy
    Leuk Lymphoma 53:2262-8. 2012
    ..01). Bendamustine and ara-c are highly synergistic on T- and B-cell lymphoma cells and cell lines, similar to MCL, overcoming resistance to the single agents...
  27. doi request reprint The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia
    Carlo Visco
    Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy
    Am J Hematol 88:289-93. 2013
    ..R-BAC is an active regimen in R/R heavily pretreated high-risk patients with CLL, representing an option for the treatment of patients that are usually refractory to standard therapy...
  28. pmc Isolated erythrocytosis: study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene
    Elena Albiero
    Department of Cellular Therapies and Haematology, San Bortolo Hospital, Vicenza, Italy
    Haematologica 97:123-7. 2012
    ..Identification of the disease-causing genes will be of critical importance for a better classification of familial and acquired erythrocytosis, offering additional insight into the erythropoietin regulating oxygen sensing pathway...
  29. pmc Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia
    Alessandra Carobbio
    Department of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Blood 112:3135-7. 2008
    ..These data challenge the theory that elevated platelet count increases thrombosis risk in ET and suggest prospective clinical trials to support this hypothesis...
  30. ncbi request reprint Intraindividual consistency of the activated protein C resistance phenotype
    Alberto Tosetto
    Hemophilia and Thrombosis Centre, Department of Haematology, S Bortolo Hospital, Vicenza, Italy
    Br J Haematol 126:405-9. 2004
    ..4%) were carriers of the G20210A prothrombin allele. APC resistance not due to FV Leiden is a frequent and consistent phenotype in the general population, with a possibly strong genetic influence...
  31. ncbi request reprint Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey
    Marco Ruggeri
    Department of Hematology, San Bortolo Hospital, Vicenza, Italy
    Blood 111:666-71. 2008
    ..A high proportion of PV and ET surgeries was complicated by vascular occlusion (7.7%) or by a major hemorrhage (7.3%). Prospective investigations analyzing the optimal prophylaxis in these patients are suggested...
  32. doi request reprint Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance
    Giancarlo Castaman
    Department of Hematology and Hemophilia and Thrombosis Center, San Bortolo Hospital, Vicenza, Italy
    Thromb Haemost 105:647-54. 2011
    ..In conclusion, similar to patients with type 1 VWD, also in patients with increased VWF clearance desmopressin maintains a major therapeutic role...
  33. doi request reprint Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD
    Giancarlo Castaman
    Department of Hematology, San Bortolo Hospital, Vicenza, Italy
    Blood 111:3531-9. 2008
    ..The presence of subtle multimeric abnormalities did not hamper potential clinically useful responses, as in typical type 1 VWD...
  34. ncbi request reprint A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD)
    A Tosetto
    San Bortolo Hospital, Vicenza, Italy
    J Thromb Haemost 4:766-73. 2006
    ..A quantitative description of bleeding symptoms in type 1 von Willebrand disease (VWD) has never been reported...
  35. ncbi request reprint Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C?
    Carlo Visco
    Department of Hematology, S Bortolo Hospital, Vicenza, Italy
    Leuk Lymphoma 55:1261-5. 2014
    ..Our findings suggest that autoimmune cytopenias at CLL diagnosis have a negative impact on patient outcome. ..
  36. doi request reprint Association of plasma fibrinogen, C-reactive protein and G-455>A polymorphism with early atherosclerosis in the VITA Project cohort
    Alberto Tosetto
    Department of Hematology, S Bortolo Hospital, Vicenza, Italy
    Thromb Haemost 105:329-35. 2011
    ..5 mg/dl. A persistent increase of plasma fibrinogen is associated with an increased risk of early atherosclerosis...
  37. ncbi request reprint Assessing bleeding in von Willebrand disease with bleeding score
    Alberto Tosetto
    Hematology Department, S Bortolo Hospital, 36100 Vicenza, Italy
    Blood Rev 21:89-97. 2007
    ..Therefore, BS represent a promising clinical tool for the analysis of bleeding in VWD, although further validation is warranted before an extensive use in clinical practice could be purported...
  38. ncbi request reprint Epidermal growth factor, basic fibroblast growth factor and platelet-derived growth factor-bb can substitute for fetal bovine serum and compete with human platelet-rich plasma in the ex vivo expansion of mesenchymal stromal cells derived from adipose tiss
    Katia Chieregato
    Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy
    Cytotherapy 13:933-43. 2011
    ..We analyzed the effect of four different medium supplements on the expansion and differentiation of adipose tissue-derived MSC (ADSC) in order to avoid the use of xenogeneic serum...
  39. ncbi request reprint Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study
    G Castaman
    Department of Hematology, S Bortolo Hospital, Vicenza, Italy
    J Thromb Haemost 4:2164-9. 2006
    ..We undertook an international, multicenter study to describe the clinical picture and to estimate the bleeding risk in a group of obligatory carriers of type 3 von Willebrand disease (VWD)...
  40. ncbi request reprint Multivariate statistical data analysis as a tool to analyze ex vivo expansion dynamics of cytokine-induced killer cells
    Cristina Zanon
    Advanced Cellular Therapy Laboratory, Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, 36100, Italy
    Cytometry B Clin Cytom 86:257-62. 2014
    ..Based on cytofluorimetric data, we have retrospectively applied multivariate statistical data analysis (MVDA) to 30 expansions building mathematical models able to predict the expansion fate and the optimal CIK harvesting day...
  41. ncbi request reprint Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia
    Carlo Visco
    Department of Hematology, Ospedale San Bortolo, Vicenza, Italy
    Blood 111:1110-6. 2008
    ..Patients with CLL and IT had poorer survival than other patients with CLL (5-year overall survival 64% vs 82%, P < .001), and this effect was independent from common clinical prognostic variables...
  42. doi request reprint Treatment outcome in a cohort of young patients with polycythemia vera
    Marco Ruggeri
    Department of Cell Therapy and Hematology, San Bortolo Hospital, Viale Rodolfi 37, Vicenza, Italy
    Intern Emerg Med 5:411-3. 2010
    ..With this approach, vascular complications were no higher than in other published series, and secondary leukemia/myelodysplasia or cancer was not observed during a follow-up of 14 years...
  43. doi request reprint Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia
    Carlo Visco
    Department of Hematology S Bortolo Hospital, Vicenza, Italy
    Am J Hematol 88:277-82. 2013
    ..This may help correct stratification within clinical trials...
  44. doi request reprint Loss of the JAK2 intramolecular auto-inhibition mechanism is predicted by structural modelling of a novel exon 12 insertion mutation in a case of idiopathic erythrocytosis
    Elena Albiero
    Department of Cellular Therapy and Haematology, San Bortolo Hospital, Vicenza, Italy
    Br J Haematol 142:986-90. 2008
    ..Our model-based hypothesis provides a useful approach for the investigation of the phenotype-genotype relationship in myeloproliferative disorders involving JAK2...
  45. ncbi request reprint Flow cytometry in the diagnosis of drug-induced thrombocytopenia: two illustrative cases
    Francesca Scognamiglio
    Department of Hematology, San Bortolo Hospital, Vicenza, Italy
    Am J Hematol 83:326-9. 2008
    ....
  46. ncbi request reprint Hemostatic complications of angiogenesis inhibitors in cancer patients
    Francesca Elice
    Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy
    Am J Hematol 83:862-70. 2008
    ..Further studies are urgently required to better define the causal association of these new agents with hemostatic complications and to establish the best prophylactic strategy...
  47. ncbi request reprint Effect of platelet lysate on the functional and molecular characteristics of mesenchymal stem cells isolated from adipose tissue
    Silvia Castegnaro
    Department of Cell Therapy and Haematology, San Bortolo Hospital, Vicenza, Italy
    Curr Stem Cell Res Ther 6:105-14. 2011
    ..They can be isolated from several tissues, but it is always necessary to expand them for clinical practice...
  48. doi request reprint Identical IGHV-D-J gene rearrangement may precede the clinical onset of chronic lymphocytic leukemia by several years
    Maurizio Frezzato
    Department of Cell Therapy and Hematology, S Bortolo Hospital, Vicenza, Italy
    Am J Hematol 85:868-71. 2010
    ..No additional rearrangements or mutations in the rearranged gene were found during follow-up. An identical clonal IGH gene rearrangement may precede CLL diagnosis by several years...
  49. ncbi request reprint The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis
    Marco Ruggeri
    S Bortolo Hospital, Vicenza, Italy
    Ann Intern Med 139:470-5. 2003
    ..The clinical relevance of mild erythrocytosis (hematocrit > 0.48 in women or > 0.51 in men) or thrombocytosis (platelet count > 400 x 10(9) cells/L) in asymptomatic persons is uncertain...
  50. doi request reprint Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study
    Roberto Raimondi
    Department of Hematology, S Bortolo Hospital, Vicenza, Italy
    Blood 120:1327-33. 2012
    ..66, 064, and 0.59, respectively). We confirm the clinical utility of the HCT-CI score that could also identify patients at low NRM risk possibly benefiting from an HSCT-based treatment strategy...
  51. ncbi request reprint A novel family with recessive von Willebrand disease due to compound heterozygosity for a splice site mutation and a missense mutation in the von Willebrand factor gene
    Giancarlo Castaman
    Department of Hematology and Hemophilia, San Bortolo Hospital, I 36100 Vicenza, Italy
    Thromb Res 105:135-8. 2002
    ..These mutations are truly recessive and cause bleeding only in the compound heterozygous or homozygous state...
  52. doi request reprint Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach
    Alberto Tosetto
    Hematology Department, San Bortolo Hospital, Vicenza, Italy
    Blood 111:3998-4003. 2008
    ..0 (false-positive rate less than one-half). Validation of this approach and of its clinical utility is, however, required by analysis in other cohorts of well-characterized type 1 VWD patients...
  53. ncbi request reprint A novel heterozygous missense mutation (His127Arg) in a family with inherited cross-reacting material positive factor XI deficiency
    Giancarlo Castaman
    Department of Cell Therapy and Hematology, Hemophilia and Thrombosis Center, San Bortolo Hospital, Vicenza, Italy
    Blood Coagul Fibrinolysis 24:670-2. 2013
    ..We describe here a novel CRM+ mutation (His127Arg) identified in an asymptomatic woman from Indonesia and in her two sons. ..
  54. doi request reprint Absence of micronucleus formation in CHO-K1 cells cultivated in platelet lysate enriched medium
    Martina Bernardi
    Hematology Project Foundation Research Laboratories, Contrà S Francesco 41, Vicenza, Italy Advanced Cellular Therapy Laboratory, Department of Cellular Therapy and Hematology, San Bortolo Hospital, Via Rodolfi 37, Vicenza, Italy
    Exp Toxicol Pathol 66:111-6. 2014
    ..Micronucleus testing in conjunction with HCS could represent a valid tool to evaluate the safety of ancillary materials used in the production of cell-based medicinal products. ..
  55. doi request reprint Immune thrombocytopenia in patients with chronic lymphocytic leukemia is associated with stereotyped B-cell receptors
    Carlo Visco
    Department of Hematology, Ospedale San Bortolo, Vicenza, Milano, Italy
    Clin Cancer Res 18:1870-8. 2012
    ..To assess biologic features related to the development of immune thrombocytopenia (ITP) in patients with chronic lymphocytic leukemia (CLL)...
  56. ncbi request reprint Side effects of anti-angiogenic drugs
    Francesca Elice
    Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy
    Thromb Res 129:S50-3. 2012
    ..So far, only few preliminary data are available on a strategy to prevent hemorrhage and thrombotic event...
  57. doi request reprint Thrombosis associated with angiogenesis inhibitors
    Francesca Elice
    Department of Cell Therapy and Haematology, San Bortolo Hospital, Via Rodolfi 37, 36100 Vicenza, Italy
    Best Pract Res Clin Haematol 22:115-28. 2009
    ..In addition, careful reporting of haemostatic complications during treatment with new anti-angiogenic drugs is warranted...
  58. doi request reprint Advances in the diagnosis and management of type 1 von Willebrand disease
    Giancarlo Castaman
    Department of Cell Therapy and Hematology and Hemophilia and Thrombosis Center, San Bortolo Hospital, 36100 Vicenza, Italy
    Expert Rev Hematol 4:95-106. 2011
    ....
  59. pmc Pregnancy and delivery in women with von Willebrand's disease and different von Willebrand factor mutations
    Giancarlo Castaman
    Department of Cell Therapy and Hematology, San Bortolo Hospital, I 36100 Vicenza, Italy
    Haematologica 95:963-9. 2010
    ..Pregnancy in von Willebrand's disease may carry a significant risk of bleeding. Information on changes in factor VIII and von Willebrand factor and pregnancy outcome in relation to von Willebrand factor gene mutations are very scanty...
  60. doi request reprint Treatment practices in adults with chronic immune thrombocytopenia - a European perspective
    Francesco Rodeghiero
    Department of Cellular Therapy and Haematology, Ospedale S, Bortolo di Vicenza, Italy
    Eur J Haematol 84:160-8. 2010
    ..It also identified perceived shortcomings of existing therapies and the need to establish an evidence base for newer interventions that could potentially make lasting response to treatment with fewer adverse effects an achievable goal...
  61. ncbi request reprint Prognostic significance of CD56 antigen expression in acute myeloid leukemia
    Eros Di Bona
    Department of Cellular Therapy and Hematology, Division of Hematology, San Bartolo Hospital, Vicenza, Italy
    Haematologica 87:250-6. 2002
    ..We investigated CD56 expression in a cohort of AML patients in order to assess its frequency and prognostic relevance...
  62. ncbi request reprint Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia
    E Di Bona
    Divisione di Ematologia, Ospedale San Bortolo, Vicenza Ematologia, Dipartimento di Biotecnologie Cellulari ed Ematologia, Universita La Sapienza, Rome, Italy
    Br J Haematol 108:689-95. 2000
    ....
  63. ncbi request reprint Reduced von Willebrand factor survival in von Willebrand disease: pathophysiologic and clinical relevance
    G Castaman
    Department of Hematology and Hemophilia and Thrombosis Center, San Bortolo Hospital, Vicenza, Italy
    J Thromb Haemost 7:71-4. 2009
    ..Recent evidence suggests that liver and spleen macrophages are responsible for VWF clearance through uptake and endocellular degradation, but it is still not known why some VWF mutants are more prone to increased clearance...
  64. doi request reprint Molecular and phenotypic determinants of the response to desmopressin in adult patients with mild hemophilia A
    G Castaman
    Department of Cell Therapy and Hematology, Hemophilia and Thrombosis Center, San Bortolo Hospital, Vicenza, Italy
    J Thromb Haemost 7:1824-31. 2009
    ..The relationship of the biologic response to desmopressin with the F8 mutation and physiological characteristics has been poorly investigated in patients with mild hemophilia A...
  65. ncbi request reprint Autosomal recessive von Willebrand disease associated with compound heterozygosity for a novel nonsense mutation (2908 del C) and the missense mutation C2362F: definite evidence for the non-penetrance of the C2362F mutation
    G Castaman
    Department of Hematology and Hemophilia and Thrombosis Center, San Bortolo Hospital, Vicenza, Italy
    Am J Hematol 82:376-80. 2007
    ..In conclusion, the mutation C2362F is frequently observed in compound heterozygosity with null alleles in patients with recessive VWD in the Veneto region and cause bleeding only in the compound heterozygous or homozygous state...
  66. ncbi request reprint Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation
    G Castaman
    Department of Hematology, Hemophilia and Thrombosis Center, San Bortolo Hospital, Vicenza, Italy
    Thromb Haemost 82:1065-70. 1999
    ..Further research should clarify whether in families with more severe clinical and laboratory phenotype a clear association with markers of VWF is found...
  67. ncbi request reprint F8 mRNA studies in haemophilia A patients with different splice site mutations
    G Castaman
    Department of Cell Therapy and Hematology, Hemophilia and Thrombosis Center, San Bortolo Hospital, Vicenza, Italy
    Haemophilia 16:786-90. 2010
    ..Both mutations were identified in severe HA. F8 mRNA analysis is a useful tool for the characterization of the mechanisms by which splice site mutations affect the phenotype, while in silico analysis may not be always reliable...
  68. ncbi request reprint Spectrum of mutations in Albanian patients with haemophilia A: identification of ten novel mutations in the factor VIII gene
    G Castaman
    Department of Hematology and Hemophilia and Thrombosis Center, San Bortolo Hospital, Vicenza, Italy
    Haemophilia 13:311-6. 2007
    ..These results further emphasize the extreme heterogeneity of the molecular basis of haemophilia A. The low prevalence of intron 22 inversion in Albanian patients with severe haemophilia A should be addressed by further studies...
  69. ncbi request reprint Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis
    G Castaman
    Department of Haematology and the Haemophilia and Thrombosis Centre, San Bortolo Hospital, Vicenza, Italy
    Br J Haematol 106:232-6. 1999
    ..01). Pseudohomozygosity for APC resistance carries a significantly higher risk for venous thromboembolism in comparison to normal subjects, but probably not in comparison to heterozygous FV Leiden carriers...
  70. ncbi request reprint Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD
    G Castaman
    Department of Hematology, San Bortolo Hospital, Vicenza, Italy
    Thromb Res 126:227-31. 2010
    ..Accurate measurement of von Willebrand factor (VWF) is a critical requirement for the diagnosis of von Willebrand disease (VWD)...
  71. ncbi request reprint Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect
    G Castaman
    Department of Hematology and Hemophilia and Thrombosis Center, San Bortolo Hospital, Vicenza, Italy
    J Thromb Haemost 4:357-60. 2006
    ..No data on FVIII/VWF changes after desmopressin and during pregnancy in patients with phenotypic VWD Vicenza has been reported...
  72. doi request reprint Autosomal recessive von Willebrand disease type 1 or 2 due to homozygous or compound heterozygous mutations in the von Willebrand factor gene. A single center experience on molecular heterogeneity and laboratory features in 12 families
    G Castaman
    Department of Hematology and Hemophilia and Thrombosis Center, San Bortolo Hospital, Vicenza, Italy
    Acta Haematol 121:106-10. 2009
    ..We report our experience with 12 families with clearly recessive inheritance, but definitely measurable factor VIII and VWF, which is not typical for severe type 3 VWD...
  73. ncbi request reprint Molecular characterization of five Italian families with inherited severe factor XIII deficiency
    G Castaman
    Department of Hematology, San Bortolo Hospital, Vicenza, Italy
    Haemophilia 14:96-102. 2008
    ..Structural analysis shows that Pro186Leu mutation leads to the replacement of the rigid proline pyrrolidine ring by the larger and more flexible leucine side chain and Ser708Asn may probably disrupt the hydrogen bond with Ala291...
  74. ncbi request reprint Autosomal dominant type 1 von willebrand disease due to G3639T mutation (C1130F) in exon 26 of von Willebrand factor gene: description of five Italian families and evidence for a founder effect
    G Castaman
    Department of Haematology and Haemophilia and Thrombosis Centre, San Bortolo Hospital, Vicenza, Italy
    Br J Haematol 108:876-9. 2000
    ..The patients responded well to desmopressin infusion. The C1130F mutation might have a dominant negative effect on the secretion of the normal protein that desmopressin would appear to overcome...
  75. ncbi request reprint The A20210 allele in the prothrombin gene enhances the risk of venous thrombosis in carriers of inherited protein S deficiency
    G Castaman
    Department of Hematology, San Bortolo Hospital, Vicenza, Italy
    Blood Coagul Fibrinolysis 11:321-6. 2000
    ..7-5.41; P = 0.1). In conclusion, the presence of the prothrombin mutation seems to increase the risk of VT carriers of protein S deficiency, although additional families are required to fully estimate the magnitude of risk...
  76. ncbi request reprint Phenotypic APC resistance in carriers of the A20210 prothrombin mutation is associated with an increased risk of venous thrombosis
    G Castaman
    Department of Hematology and Hemophilia and Thrombosis Center, San Bortolo Hospital, Vicenza, Italy
    Thromb Haemost 86:804-8. 2001
    ..01-1.30). In conclusion, in subjects with G20210A mutation APC resistance is significantly increased, correlates with plasma prothrombin level and the carriers with the lowest APC resistance values have an increased risk of VTE...
  77. ncbi request reprint ABO-incompatible bone marrow transplantation: a GITMO survey of current practice in Italy and comparison with the literature
    R Raimondi
    Department of Haematology, BMT Unit, S Bortolo Hospital, Vicenza, Italy
    Bone Marrow Transplant 34:321-9. 2004
    ....
  78. ncbi request reprint Homozygous type 2N R854W von Willebrand factor is poorly secreted and causes a severe von Willebrand disease phenotype
    G Castaman
    Department of Cellular Therapy and Haematology, San Bortolo Hospital, Vicenza, Italy
    J Thromb Haemost 8:2011-6. 2010
    ..The R854Q mutation is the most frequent cause of this phenotype...
  79. ncbi request reprint Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di M
    E Di Bona
    Haematology Department, San Bortolo Hospital, Vicenza, Italy
    Br J Haematol 107:330-4. 1999
    ..Female gender was significantly associated with a poorer likelihood to respond (P = 0.0006). These data suggest that r-ATG is a safe and effective alternative to h-ALG for SAA patients unresponsive to first-line IS treatment...
  80. doi request reprint Severe spontaneous arterial thrombotic manifestations in patients with inherited hypo- and afibrinogenemia
    G Castaman
    Department of Hematology and Hemophilia, San Bortolo Hospital, Vicenza, Italy
    Haemophilia 15:533-7. 2009
    ..Thrombotic events in patients with inherited severe hypofibrinogenemia are rather frequent, may be severe and not associated with the use of replacement therapy...
  81. ncbi request reprint Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V Leiden) and His1299Arg substitutions in factor V
    G Castaman
    Department of Haematology and Haemophilia and Thrombosis Centre, San Bortolo Hospital, Vicenza, Italy
    Br J Haematol 99:257-61. 1997
    ..These data confirm that genotypic analysis is mandatory in patients with phenotypic severe APC resistance before these patients are definitely classified as homozygotes for FV Leiden and that further genotypic analysis is advisable...
  82. doi request reprint Alterations of mRNA processing and stability as a pathogenic mechanism in von Willebrand factor quantitative deficiencies
    G Castaman
    Department of Cell Therapy and Hematology, Hemophilia and Thrombosis Center, San Bortolo Hospital, Vicenza, Italy
    J Thromb Haemost 8:2736-42. 2010
    ..While VWD mutations acting at the protein level have been deeply investigated, fewer data are available on genetic defects affecting VWF mRNA...
  83. doi request reprint Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials
    Francesco Rodeghiero
    San Bortolo Hospital, Vicenza, Italy
    Eur J Haematol 91:423-36. 2013
    ..We sought to determine the long-term tolerability of the TPOra romiplostim, with a particular focus on thrombosis, bleeding, bone marrow (BM) reticulin, neoplasms/haematological malignancies and fatal events...
  84. ncbi request reprint Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from literature analysis
    Marco Ruggeri
    Division of Hematology, S Bortolo Hospital, Vicenza, Italy
    Pediatr Blood Cancer 47:653-6. 2006
    ..The study revealed confounding terminology and an unacceptable heterogeneity for clinical definitions relevant to management decisions and outcomes reporting...
  85. ncbi request reprint Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma
    Elisabetta Novella
    Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy
    Haematologica 87:1157-64. 2002
    ....
  86. ncbi request reprint Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia
    Marco Ruggeri
    Department of Hematology, S Bortolo Hospital, Vicenza, Italy
    Am J Hematol 71:1-6. 2002
    ..FV Leiden mutation is a risk factor for VTE before and at time of diagnosis and for VTE recurrences. Screening for FV Leiden may be considered to identify PV and ET patients at higher risk of recurrences...
  87. doi request reprint Factor XI gene mutations in factor XI deficient patients of the Czech Republic
    Giancarlo Castaman
    Department of Hematology and Hemophilia and Thrombosis Center, San Bortolo Hospital, Vicenza, Italy
    Am J Hematol 83:916-9. 2008
    ....
  88. ncbi request reprint Bleeding scores in inherited bleeding disorders: clinical or research tools?
    A Tosetto
    Hematology Department, S Bortolo Hospital, Vicenza, Italy
    Haemophilia 14:415-22. 2008
    ....
  89. ncbi request reprint Multiplex amplification and fluorimetric detection of short tandem repeats for mixed chimerism after bone marrow transplant
    Domenico Madeo
    Department of Cell Therapy and Hematology, San Bortolo Hospital, via Rodolfi, 37, 36100 Vicenza, Italy
    Leuk Lymphoma 44:1395-404. 2003
    ..In conclusion, the proposed method is sufficiently simple, rapid, sensible, specific and cost effective for the evaluation of mixed chimerism after BM or PBSC transplant in a clinical setting...
  90. ncbi request reprint Thalidomide and thrombosis
    Francesco Rodeghiero
    Department of Hematology, San Bortolo Hospital, Vicenza, Italy
    Pathophysiol Haemost Thromb 33:15-8. 2003
  91. ncbi request reprint Prevalence and risk factors of non-fatal venous thromboembolism in the active population of the VITA Project
    A Tosetto
    Hematology Department, S Bortolo Hospital, Vicenza, Italy
    J Thromb Haemost 1:1724-9. 2003
    ..In 30% of VTE cases, at least two easily recognizable risk factors are present. Clinical assessment of risk factors remains the mainstay of VTE prevention...
  92. ncbi request reprint Congenital von Willebrand disease type I: definition, phenotypes, clinical and laboratory assessment
    F Rodeghiero
    Department of Hematology and Hemophilia, Thrombosis Center, San Bortolo Hospital, 36100 Vicenza, Italy
    Best Pract Res Clin Haematol 14:321-35. 2001
    ..We present a practical approach to diagnosis, based on scientific evidence and direct experience. The implications of the diagnosis of von Willebrand disease for the patient's quality of life are also considered...
  93. ncbi request reprint Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients
    Eros Di Bona
    Department of Haematology, Vicenza Hospital, Vicenza, Italy
    Leuk Lymphoma 46:879-84. 2005
    ..In spite of 12 HSCTs, there was no long-term survivor. 'ABC' salvage proved feasible and comparable to reported rescue chemotherapic regimens, but the achievement of cure in refractory/relapsing ALL remains an outstanding clinical task...
  94. ncbi request reprint Immune thrombocytopenia in lymphoproliferative disorders
    Carlo Visco
    Division of Hematology, Department of Cell Therapy and Hematology, San Bortolo Hospital, Via Rodolfi 37, Vicenza 36100, Italy
    Hematol Oncol Clin North Am 23:1261-74. 2009
    ..A better understanding of the responsible mechanisms leading to ITP in each disease may allow for targeted treatment decisions, avoiding unwarranted immunosuppression and bleeding complications...
  95. doi request reprint Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact
    F Elice
    Department of Hematology and Cell Therapy, San Bortolo Hospital, Vicenza, Italy
    Thromb Res 125:S55-7. 2010
    ....
  96. ncbi request reprint Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy
    C Visco
    Department of Hematology, Ospedale S Bortolo, Vicenza, Italy
    Ann Oncol 17:1434-40. 2006
    ..Diffuse large B-cell lymphoma (DLBCL) has been correlated to hepatitis C virus (HCV) infection in few series, but characteristics and outcome of these patients remain undefined...
  97. ncbi request reprint Age-adjusted reference limits for carotid intima-media thickness as better indicator of vascular risk: population-based estimates from the VITA project
    A Tosetto
    Department of Hematology, S Bortolo Hospital, Vicenza, Italy
    J Thromb Haemost 3:1224-30. 2005
    ....
  98. ncbi request reprint Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in adults
    Donato Gemmati
    Department of Biomedical Sciences and Advanced Therapies, Center Study for Hemostasis and Thrombosis, University of Ferrara, C so Giovecca 203, I 44100 Ferrara, Italy
    Cancer Epidemiol Biomarkers Prev 13:787-94. 2004
    ..These data are in accordance with the hypothesis that polymorphisms in the genes for folate and methionine metabolism might play a greater role in the occurrence of ALL than NHL by influencing DNA synthesis and/or DNA methylation...
  99. pmc Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD)
    Sandra L Haberichter
    Department of Pediatrics, Medical College of Wisconsin, Milwaukee, USA
    Blood 111:4979-85. 2008
    ..The systematic assay of both plasma VWF and the VWF propeptide in moderately severe type 1 VWD patients may identify patients with a reduced VWF survival phenotype...
  100. ncbi request reprint Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD)
    Anne Goodeve
    The Academic Unit of Haematology, University of Sheffield, United Kingdom
    Blood 109:112-21. 2007
    ..About one third of the type 1 VWD cases recruited could be reconsidered as type 2. The remaining group could be considered "true" type 1 VWD, although mutations were found in only 55%...
  101. ncbi request reprint Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment
    Giancarlo Castaman
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital and University of Milan, Italy
    Haematologica 88:94-108. 2003
    ..Bleeding manifestations are heterogeneous: mucosal bleeding is typical of all VWD cases but hemarthrosis and hematomas may also be present when FVIII levels are low...